ScripMerger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu
ScripAlthough Novartis’s immunoglobulin A nephropathy (IgAN) franchise will face considerable competition from other firms, the accelerated approval in the US of Vanrafia (atrasentan) further solidifies it
ScripCullinan Therapeutics and Taiho have a significant market opportunity with zipalertinib after successful results in the Phase I/II REZILIENT1 trial among previously treated non-small cell lung cancer
Pink SheetThe US Food and Drug Administration is in the early phases of reconsidering the long-standing class-wide “black box” warning for antipsychotics citing increased mortality in older adults with dementia